Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apligraf pressure sore trials imminent:

This article was originally published in Clinica

Executive Summary

Organogenesis is to begin clinical trials in the new year of its Apligraf manufactured skin product to treat pressure sores. The FDA is considering the use of Apligraf, formerly known as Graftskin, in venous ulcers. US studies with diabetic ulcers are underway (see Clinica No 776, p 17). Apligraf is marketed in Canada for venous ulcers by Novartis Pharmaceuticals.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT086828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel